Loading
1,497 genes and proteins the open catalogues tie to cancer, each with its own page, registry identifiers and the sources it was read from, grouped here by what they do and by how strong the evidence is. 1,442 were written from the catalogues on 2026-09-23; 177 older target pages carry no role yet.
The gene list is the union of three open catalogues: CIViC (community-curated clinical interpretations of variants, CC0), Open Targets (targets associated with cancer, MONDO_0004992, by direct and indirect evidence at a stated score, CC0) and IntOGen (drivers called by mutation analysis of patient cohorts, release 2024-09-20, CC0 1.0). Identifiers and aliases come from HGNC; the plain-English function text is UniProt's (CC BY 4.0), condensed and put into UK spelling, not rewritten. No licensed list (OncoKB, COSMIC) was used. Cancers are linked only where a catalogue ties the gene to a cancer that has an OnCo page; disease names that map to nothing are kept in each record's notes rather than guessed. Roles and evidence tiers are derived from the catalogue fields named on every page, and each page ends with a Sources line.
Machine-readable: all targets as JSON (fields role, evidenceTier, sources, hgnc, ensembl, uniprot, entrez) · CSV · field definitions · rebuilt by scripts/fetch-cancer-genes.ts.
A drug acting on the target has reached late-stage trials or approval for a cancer.
Clinical evidence items on its variants, or a drug in early trials, but nothing approved.
Called a driver by cohort mutation analysis; no clinical evidence yet.
Association with cancer in the aggregated evidence, without a proven role.
The medicine aims at an altered form of the protein (a mutation, a fusion or a neoantigen) that normal cells do not carry.
Normal tissue carries the target too, at lower levels; the medicine relies on the tumour carrying much more of it.
The target sits on one normal cell lineage (B cells, plasma cells, myeloid cells) as well as on the cancer that grew from it.
Nearly every dividing cell carries or depends on the target; the medicine works because tumour cells divide faster or depend on it more.
The alteration is inherited and present in every cell of the body; it shapes cancer risk and picks medicines that exploit the loss.
The target is on immune, stromal or bone cells around the tumour, not on the tumour cell itself.
A drug in trials or on the market acts on the protein (Open Targets known-drug evidence, CIViC therapies, or an OnCo product record that names it).
Approved drug 219Clinical evidence 315Association only 3
Mutation analysis of patient cohorts finds the gene activated more often than chance allows (IntOGen role Act).
Approved drug 19Clinical evidence 159Driver by cohort analysis 209
Mutation analysis of patient cohorts finds the gene knocked out more often than chance allows (IntOGen role LoF).
Approved drug 19Clinical evidence 153Driver by cohort analysis 217Association only 1
Curated clinical evidence ties its variants to diagnosis, prognosis or drug response (CIViC evidence items).
Approved drug 39Clinical evidence 453Association only 11
UniProt records a chromosomal translocation or gene fusion involving the gene.
Approved drug 10Clinical evidence 33Driver by cohort analysis 71Association only 53
UniProt keyword DNA repair or DNA damage: the protein keeps the genome intact, which is why its loss sensitises tumours to some drugs.
Approved drug 16Clinical evidence 51Driver by cohort analysis 7Association only 32
UniProt describes the protein as an immune checkpoint that restrains T cells.
Approved drug 2Clinical evidence 4Driver by cohort analysis 1
A membrane or secreted protein that antibody-based products (ADCs, bispecifics, CAR-T, radioligands) use as a docking site.
Each role above lists its first 30 genes and fetches the rest as you scroll, press Show more or set a filter. All 1,497 genes as JSON (symbol, page, roles, evidence tier, in the order shown) · full target records · API